Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.84 |
| ▸ | GFER | P55789 | 1/20 | 0.79 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.78 |
| ▸ | AANAT | Q16613 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | MMP9 | P14780 | 1/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7849865 | 0.93 | MEN1 (0.74) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL9117842 | 0.92 | MEN1 (0.76) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL7852879 | 0.92 | GFER (0.84) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL7973988 | 0.92 | MEN1 (0.71) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL19051489 | 0.92 | MEN1 (0.80) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL761481 | 0.92 | MTNR1A (0.88) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL7851164 | 0.91 | MEN1 (0.71) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL9303912 | 0.91 | MEN1 (0.71) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL9303476 | 0.91 | MEN1 (0.71) | MEN1KMT2AGFERMTNR1AAANAT | |
| SCHEMBL9302879 | 0.91 | MEN1 (0.71) | MEN1KMT2AGFERMTNR1AAANAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309606-B2 | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2012-11-13 | — | — | US | disclosed |
| US-8309606-B2 | Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2012-11-13 | — | — | US | disclosed |
| US-8252843-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2012-08-28 | — | — | US | disclosed |
| US-8252843-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2012-08-28 | — | — | US | disclosed |
| US-20100331383-A1 | COMPOUNDS FOR THE TREATMENT OF AIDS AND OTHER VIRAL DISEASES | NOVAREMED LIMITED (IL) | 2010-12-30 | — | — | US | disclosed |
| US-20100331383-A1 | COMPOUNDS FOR THE TREATMENT OF AIDS AND OTHER VIRAL DISEASES | NOVAREMED LIMITED (IL) | 2010-12-30 | — | — | US | disclosed |
| US-7754771-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-07-13 | — | — | US | disclosed |
| US-7754771-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-07-13 | — | — | US | disclosed |
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2010-03-18 | — | — | US | disclosed |
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | NOVAREMED LIMITED (IL) | 2010-03-18 | — | — | US | disclosed |
| US-7674829-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-03-09 | — | — | US | disclosed |
| US-7674829-B2 | Compounds for the treatment of AIDS and other viral diseases | NOVAREMED LIMITED (IL) | 2010-03-09 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-7642290-B2 | lupus erythematosus; enoephalomyelitis; graft-versus-host disease | NOVAREMED LIMITED (IL) | 2010-01-05 | — | — | US | disclosed |
| US-6472418-B1 | Non-peptide NK1 receptors antagonists | WARNER-LAMBERT COMPANY | 2002-10-29 | — | — | US | disclosed |
| EP-1140914-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037462-A1 | NON-PEPTIDE NK1 RECEPTORS ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 2000-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069454-A1 | Novel compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection | TSLP, HLA-DRB1, MRGPRX2 | MEN1 3418/4885KMT2A 3181/4885GFER 1943/4885 |
| US-20100331383-A1 | COMPOUNDS FOR THE TREATMENT OF AIDS AND OTHER VIRAL DISEASES | CCR4, CD4, CCR5 | MEN1 2032/4885KMT2A 1683/4885GFER 2306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.